International Journal of Heart Failure · Oct 8, 2026
Natriuretic Peptides for Predicting Treatment Response in Heart Failure: Insights From Recent Randomized Controlled Trials
By Oh HE, Hyun J
N-terminal pro-B-type natriuretic peptide (NT-proBNP) has emerged as a cornerstone biomarker in heart failure (HF), serving as a diagnostic, prognostic, and pharmacodynamic tool in randomized controlled trials. Recent HF trials have generated substantial evidence regarding 2 interrelated roles: (1) the relationship between baseline NT-proBNP levels and differential treatment efficacy across drug classes, and (2) the proportional relationship between NT-proBNP reduction and clinical outcome improvement. We synthesize data from pivotal trials of sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor, ARNI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRAs), vericiguat, and omecamtiv mecarbil. Across trials in both HF with reduced ejection fraction and HF with mildly reduced or preserved ejection fraction, some drug classes including ARNI, SGLT2 inhibitors, MRA, and device therapies demonstrated consistent relative treatment benefits regardless of baseline NT-proBNP levels. Notable exceptions were vericiguat, a soluble guanylate cyclase stimulator, where patients with higher baseline NT-proBNP derived no benefit; omecamtiv mecarbil, which showed selective benefit in patients with higher NT-proBNP levels; and spironolactone in HFpEF, where benefit was concentrated in patients with the lowest baseline NT-proBNP. With respect to NT-proBNP dynamics, a geometric mean ratio of on-treatment to baseline NT-proBNP consistently parallels the hazard ratio for clinical outcomes across ARNI trials, supporting NT-proBNP change as a robust surrogate endpoint. SGLT2 inhibitors consistently show clinical benefit exceeding the extent of NT-proBNP reduction, reflecting pleiotropic mechanisms. These insights position NT-proBNP not merely as a prognostic marker, but as an outcome-predictive biomarker that may inform patient selection and response monitoring in precision HF management.
doi.org/10.36628/ijhf.2026.0076Open accessPubMed 43011112Interventions